Premium
Pharmacokinetic/Pharmacodynamic Modelling in Oncological Drug Development
Author(s) -
Karlsson Mats O.,
Anehall Therese,
Friberg Lena E.,
Henningsson Anja,
Kloft Charlotte,
Sandström Marie,
Xie Rujia
Publication year - 2005
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/j.1742-7843.2005.pto960310.x
Subject(s) - pharmacodynamics , drug , pharmacokinetics , drug development , pharmacology , prodrug , medicine , toxicity , limiting , population , mechanical engineering , environmental health , engineering
Abstract: For many oncological agents, myelosuppression is the dose‐limiting toxicity and the quantitative characterisation of the relationship between drug dose, plasma concentration and haematological toxicity is of importance in the drug development. Mechanism‐based population pharmacokinetic‐pharmacodynamic models have been developed for this purpose and the applications of these in candidate selection, first‐in‐man studies, prodrug and formulation development, dose finding, schedule optimisation, assessing influence of modifying agents, drug combination studies, subgroup identification and feedback individualisation are reviewed.